Supplemental figure 1. Comparisons of CCR6$^+$ and CCR6$^-$ IL-17A-producing T cells in Chinese male versus Chinese female GO patients and comparisons of CCR6$^+$ and CCR6$^-$ IL-17A-producing T cells in smokers with GO versus non-smokers with GO. A The proportions of CD3$^+$CD8$^-$CCR6$^+$ IL-17A-producing T cells and CD3$^+$CD8$^-$CCR6$^-$ IL-17A-producing T cells in male GO patients and female GO patients (n=9 for male GO patients and n=21 for female GO patients) (M: male, F: female). B The proportions of CD3$^+$CD8$^-$CCR6$^+$ IL-17A-producing T cells and CD3$^+$CD8$^-$CCR6$^-$ IL-17A-producing T cells in smokers with GO and non-smokers with GO (n=13 for smokers with GO and n=17 for non-smokers with GO). Data are presented as mean ± SD. ns, nonsignificant, *, $P < .05$; **, $P < .01$; ***, $P < .001$. 
Supplemental figure 2. Gene expression of pro-inflammatory cytokines of PBMCs from GO patients and control subjects. A The expression of *Il8* gene in GO and control PBMCs with 100 ng/mL IL-17A treatment for 24 hours. B The expression of *Il6* gene in GO and control PBMCs with 100 ng/mL IL-17A treatment for 24 hours. C The expression of *MCP1* gene in GO and control PBMCs with 100 ng/mL IL-17A treatment for 24 hours. Data are presented as mean ± SD and are combined from at least three independent experiments. *P < .05, **P < .01, and ***P < .001.
Supplemental figure 3. Flow cytometric data on pro-inflammatory cytokine production of fibrocytes with IL-17A treatment in situ. A The production of IL-8 in GO and control CD34^+CD45^+CXCR4^+COL1^+ fibrocytes, with or without 100 ng/mL IL-17A treatment, in the presence or absence of α-IL-17A (0.25 μg/mL) for 24 hours. B The production of IL-6 in GO and control CD34^+CD45^+CXCR4^+COL1^+ fibrocytes, with or without 100 ng/mL IL-17A, treatment in the
presence or absence of α-IL-17A (0.25 μg/mL) for 24 hours. C The production of MCP-1 in GO and control CD34+CD45+CXCR4+COL1+ fibrocytes, with or without 100 ng/mL IL-17A treatment, in the presence or absence of α-IL-17A (0.25 μg/mL) for 24 hours (PBMCs were obtained from six GO patients and six healthy donors). Representative data are shown; data are combined from at least three independent experiments.

Supplemental figure 4. Gene expression of pro-inflammatory cytokines of fibrocytes from GO patients co-cultured with autologous Th17 cells at the indicated time points. A Up-regulated gene expression of Il6 of fibrocytes from GO patients co-cultured with autologous Th17 cells after 24 hours. B Up-regulated gene expression of Il8 of fibrocytes from GO patients co-cultured with autologous Th17 cells after 24 hours. C Up-regulated gene expression of MCP1 of fibrocytes from GO patients after 24 hours.
co-cultured with autologous Th17 cells after 24 hours. D Up-regulated gene expression of *MIP3* of fibrocytes from GO patients co-cultured with autologous Th17 cells after 24 hours. E Up-regulated gene expression of *TNFA* of fibrocytes from GO patients co-cultured with autologous Th17 cells after 24 hours. F Up-regulated gene expression of *GMCSF* of fibrocytes from GO patients co-cultured with autologous Th17 cells at after 48 hours. G Up-regulated gene expression of *Cxcl9* of fibrocytes from GO patients co-cultured with autologous Th17 cells after 24 hours. H Up-regulated gene expression of *Cxcl10* of fibrocytes from GO patients co-cultured with autologous Th17 cells after 24 hours. Data are presented as mean ± SD and are combined from at least three independent experiments. *P < .05, **P < .01, and ***P < .001.